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Abstract 
Purpose: Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly 
in Western Countries. Evidence indicates that Glucose-6-Phosphate Dehydrogenase (G6PD) 
deficiency, a common genetic abnormality, may protect against ischemic heart and cerebrovascular 
disease, ocular vascular disorders, and colorectal cancer. This study was undertaken to ascertain 
whether G6PD deficiency may protect against AMD. 
Materials and Methods: 79 men with late-stage AMD and 79 male, age-matched cataract 
controls without AMD were recruited in March-December 2016. Smoking status, clinical history, 
and drug use were recorded. A blood sample was taken from each participant. Complete blood 
count, hemoglobin, glucose, creatinine, cholesterol, triglycerides, transaminases, bilirubin, and 
erythrocyte G6PD activity were measured. Stepwise logistic regression was used to investigate the 
association between G6PD deficiency and AMD. 
Results: G6PD deficiency was found in 7 (8.9%) AMD patients and 8 (10.1%) controls, a not 
statistically significant difference. Stepwise logistic regression disclosed that AMD was significantly 
associated with increased diastolic blood pressure (OR=1.09, 95% CI=1.03-1.15, P=0.02) and 
LDL-cholesterol (OR=1.02, 95% CI=1.0001-1.03, P=0.049) and lower values of white blood cell 
(WBC) count (OR=0.71, 95% CI=0.56-0.88, P=0.02) and aspartate aminotransferase (AST) 
(OR=0.92, 95% CI=0.85-0.99, P=0.044). 
Conclusion: Results suggest that G6PD deficiency has no protective effect on nor is a risk factor 
for AMD. Larger studies are necessary to confirm whether increased diastolic blood pressure and 
LDL-cholesterol and lower values of WBC count and AST are risk factors for AMD. 
Key words: age-related macular degeneration (AMD); Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency; 
observational case-control study; stepwise logistic regression analysis 
Introduction 
Age-related macular degeneration (AMD) is a 
leading cause of severe, irreversible vision 
impairment in adults aged over 50 in the Western 
Countries.1 AMD can be classified into early and late 
stages. Early AMD is a clinical condition without 








retinal pigment epithelium alterations and/or drusen 
in the macular area.2 The late-stage manifestations of 
AMD include geographic atrophy (dry AMD) and 
neovascolar (wet) AMD. The hallmark of wet AMD is 
the presence of choroidal neovascularization (CNV), 
defined as formation of pathological neovessels 
originating from the choroidal vasculature and 
extending through a defect in the Bruch’s membrane. 
The pathological mechanisms underlying AMD are 
not clear, but clinical and experimental evidence 
indicates that genetic predisposition and 
environmental factors, such as tobacco smoking and 
oxidative stress, may play a major role.3-9  
Glucose-6-Phosphate Dehydrogenase (G6PD) is 
a ubiquitous cytoplasmic enzyme converting 
glucose-6-phosphate into 6-phosphogluconate in the 
pentose phosphate pathway. G6PD is the rate-limiting 
enzyme of this metabolic pathway that supplies 
reducing energy to cells by maintaining the level of 
the reduced form of the extramitochondrial 
Nicotine-Adenosine-Dinucleotide Phosphate 
(NADPH) coenzyme. In red blood cells, defense 
against oxidative stress is strictly dependent on G6PD 
activity, because the G6PD/NADPH pathway is the 
only source of reduced glutathione (GSH).10 The gene 
encoding G6PD is on the distal long arm of the X 
chromosome (band Xq28). Hemizygous males have 
populations of uniformly deficient erythrocytes, 
whereas heterozygous females have mosaic 
populations of normal and G6PD-deficient red blood 
cells, due to random inactivation of X chromosome. 
G6PD deficiency is genetically heterogeneous and 
about 400 different variant enzymes have been 
described.11 The G6PD-Mediterranean variant (C to T 
transition at nucleotide 563) is associated with 
undetectable levels of enzyme activity by routine 
methods (WHO class II). This variant is common in 
the island of Sardinia, Italy, where the reported 
prevalence of G6PD deficiency is 8-15%.12-18 G6PD 
deficiency represents a public health issue in Sardinia, 
because of the seasonal occurrence of favism, a 
hemolytic anemia caused by the ingestion of the 
broad bean (Vicia faba) in affected subjects.11,13  
Former studies have suggested that G6PD 
deficiency may have a protective effect on ischemic 
heart and cerebrovascular disease and colorectal 
cancer.14,19,20 Additionally, G6PD-deficient individuals 
have been reported to have a significantly decreased 
risk of developing retinal vein occlusion (RVO) and 
nonarteritic anterior ischemic optic neuropathy 
(NAION).16,21 The concept that G6PD deficiency may 
protect against the development of various 
age-related diseases is new and not yet established. 
Little is known about the role of G6PD deficiency 
in AMD. The present study was designed to assess the 
frequency of G6PD deficiency in Sardinian men with 
AMD and ascertain whether G6PD deficiency is a risk 
factor for AMD or may have a protective effect against 
this important cause of blindness in the elderly. 
Patients and Methods 
The present study used a case-control design, 
recruiting 79 consecutive men with late-stage AMD 
and 79 perfectly age-matched male controls without 
AMD between March and December 2016. Women 
were excluded because of the small number of 
homozygote subjects with complete lack of 
erythrocyte G6PD activity. Sample size was computed 
before the survey, using a two-tailed test at 5% 
significance level with an 80% statistical power to 
detect an estimated relative risk of 0.4, assuming a 
G6PD prevalence rate of 8% as reported 
previously,13,17,18 and an incidence of 25,000 new AMD 
cases per year (data from the Istituto Nazionale di 
Statistica – ISTAT, 2004, Italy). 
Institutional ethics review board approval was 
obtained and the study was conducted in full accord 
with the tenets of the Declaration of Helsinki. Each 
participant received detailed information and 
provided informed consent before inclusion.  
The inclusion criteria for cases were male 
gender, Sardinian descent, and the diagnosis of 
late-stage AMD (neovascular AMD or geographic 
atrophy involving the center of the macula) in at least 
one eye.2 All AMD patients underwent a full 
ophthalmic evaluation, including fluorescein 
angiography and OCT scans of the macula (3D 
OCT-1000 Mark II, Topcon Co, Tokyo, Japan). 
Perfectly age-matched male controls of Sardinian 
ancestry were selected among patients undergoing 
cataract surgery. All controls underwent standard 
ophthalmic evaluation, including best corrected 
visual acuity, slit-lamp examination, applanation 
tonometry, and fundus examination. Patients with 
any clinical evidence of maculopathy (i.e. early, dry or 
wet AMD, cystoid macular edema, epiretinal 
membrane, retinal pigment epithelium changes, 
central serous chorioretinopathy, diabetic macular 
edema, etc.) and/or retinal vascular disorder (retinal 
vein occlusion, diabetic retinopathy, etc.) were 
excluded. 
Medical conditions, including body mass index 
(BMI), systemic hypertension, hypercholesterolemia, 
diabetes mellitus, cardio- and cerebro-vascular status 
(positive history of angina, myocardial infarction, 
TIA, stroke), renal failure, and medication use were 
also recorded for both AMD patients and controls. 
Definitions of systemic hypertension, diabetes, and 
hypercholesterolemia have been reported 
previously.16 




Smoking history was obtained by an 
interviewer-administered questionnaire. Current 
smoking status was compared with noncurrent 
smoking (individuals who smoked in the past or 
never smoked). 
Sitting blood pressure was measured three times 
after resting for at least 5 minutes. The average of the 
three measurements was used for the analysis. 
A blood sample was taken from each participant 
after an overnight fast. Standard laboratory tests, 
including complete blood count, hemoglobin, glucose, 
creatinine, total cholesterol, HDL-cholesterol, 
LDL-cholesterol, triglycerides, transaminases (ALT 
and AST), and bilirubin were performed. Red blood 
cell G6PD activity was determined using a 
quantitative assay (G6PD/6PGD, Biomedic snc, 
Sassari, Italy), as described previously.16 
In addition, serum vitamin B12 and folate levels 
were measured in all patients with AMD. Vitamin B12 
and folate were measured using an IMX Analyzer 
(Abbott Laboratories Diagnostics Division, Abbott 
Park, IL). The IMX B12 assay is based on the 
microparticle enzyme immunoassay (MEIA) 
technology, while IMX folate is an ion capture assay 
technique. For these immunological assays, inter- and 
intra-assay coefficients of variation were <10%. 
Normal values for plasma vitamin B12 and folate are 
179-1162 pg/ml and 2.7-34 ng/ml, respectively. 
Descriptive analysis was performed for all 
variables measured. Categorical variables were 
compared by Z test for proportions and differences 
for quantitative variables were analyzed by Student’s 
t test.  
Stepwise logistic regression models were 
performed to calculate the estimates of odds ratios 
(ORs), considering AMD as dependent variable and 
including BMI, systolic blood pressure, diastolic 
blood pressure, blood glucose, creatinine, total 
cholesterol, LDL, HDL, triglycerides, white blood cell 
(WBC) count, hemoglobin, ALT and AST, bilirubin, 
G6PD deficiency, smoking status, concomitant cardio- 
and cerebro-vascular disorders (Yes/No), and use of 
antiplatelet and/or anticoagulant medications 
(Yes/No) and lipid-lowering drugs (Yes/No) as 
covariates (full model). Furthermore, interaction 
terms were added to the regression models to detect 
possible confounders. A significance level of 0.2 was 
used to remove covariates from the multivariable 
model. ORs and 95% confidence intervals (CIs) were 
obtained by a maximum likelihood estimation. P 
values <0.05 were considered to be statistically 
significant. Statistical analysis was performed with 
commercial software (STATA ver. 12; StataCorp, 
College Station, TX). 
Four percent of the AMD cases and 7% of the 
control subjects who were eligible for the study 
declined to participate. The major reason was “not 
interested.” 
Results 
The study group consisted of 79 AMD men 
(mean age: 78±7 years, range 57-92 years). The control 
group included an equal number of perfectly 
age-matched male subjects without AMD. In both 
groups, all individuals were of Sardinian ancestry.  
In the AMD group, 19 patients had bilateral wet 
AMD, 1 bilateral geographic atrophy, 3 wet AMD in 
one eye and geographic atrophy in the fellow one, and 
56 wet AMD in one eye and early AMD in the fellow 
eye. 
Wet AMD patients had received an average of 5 
intravitreal injections of an anti-VEGF agent 
(bevacizumab, ranibizumab, or aflibercept) per eye.  
The AMD and cataract groups had identical 
mean intraocular pressure values (14±2.6 mm Hg and 
14±3.5 mm Hg). Four (5%) AMD and 7 (9%) cataract 
patients had glaucoma, a not statistically significant 
difference. 
Demographics, medical history information, and 
blood test results are summarized in Table 1. All the 
diabetic patients had type 2 diabetes. Both AMD 
patients and control subjects had similar rates of 
diabetes, hypertension, hypercholesterolemia, cardio- 
and cerebro-vascular disorders, chronic renal failure, 
G6PD deficiency, smoking, and use of antiplatelet 
and/or anticoagulant medications and lipid-lowering 
drugs. Likewise, there were no significant differences 
in BMI, hemoglobin, plasma glucose, creatinine, LDL, 
triglycerides, ALT, and bilirubin values. On the other 
hand, AMD patients had significantly higher values 
of systolic and diastolic blood pressure, plasma 
cholesterol, and HDL, and significantly lower values 
of WBC count and AST. 
Mean plasma vitamin B12 and folate values in 
AMD patients fell within normal ranges (299 pg/ml 
and 5.2 ng/ml, respectively). 
Forward-stepwise selection led to a final logistic 
regression model with 8 variables, including diastolic 
blood pressure, LDL, HDL, WBC count, hemoglobin, 
AST, smoking status, and concomitant cardio- and 
cerebro-vascular disorders (Yes/No). In this model, 
logistic regression analysis showed that AMD was 
significantly associated with higher values of diastolic 
blood pressure (OR = 1.09, 95% CI = 1.03-1.15, P = 
0.02) and LDL (OR = 1.02, 95% CI = 1.0001-1.03, P = 
0.049) and lower values of WBC count (OR = 0.71, 95% 
CI = 0.56-0.88, P = 0.02) and AST (OR = 0.92, 95% CI = 
0.85-0.99, P = 0.044). No interaction term was found to 
be statistically significant. 
 





Table 1. Demographics, medical history information, and blood test results of patients with age-related macular degeneration (AMD) and 
cataract controls without AMD. 
 AMD patients (n = 79) Controls (n = 79) P values (Cases vs Controls) 
 







Diabetes mellitus, n (%)† 14 (17.7) 20 (25.3) 0.25 
Hypercholesterolemia, n (%)‡ 37 (46.8) 42 (53.2) 0.43 
Body mass index (kg/cm2), mean ± SD 27.2 ± 5.5 27.1 ±3.7 0.84 
Cardiovascular and Cerebrovascular disease, n (%) 11 (13.9) 10 (12.7) 0.82 
Chronic renal failure 3 (3.8)  2 (2.5) 0.65 
G6PD deficiency, n (%) 7 (8.9) 8 (10.1) 0.79 
Smoking, n (%) 11 (8.7) 11 (8.7) 1 
Systolic blood pressure (mm Hg), mean ± SD 141.2 ± 18.4 134.1 ± 14.4 0.0075 
Diastolic blood pressure (mm Hg), mean ± SD 80.6 ± 9.3 76.1 ± 9.9 0.0039 
White blood cell count (x103/µL) 7.0 ± 1.9 7.99 ± 2.4 0.0073 
Hemoglobin (g/dL), mean ± SD 14.0 ± 1.62 14.0 ± 2.2 0.99 
Plasma glucose (mg/dL), mean ± SD 107.8 ± 23.4 121.1 ± 57.4 0.06 
Total cholesterol (mg/dL), mean ± SD 193.3 ± 35.6 178.6 ± 42.5 0.02 
HDL (mg/dL), mean ± SD 54.7 ± 12.1 49.3 ± 12.3 0.0055 
LDL (mg/dL), mean ± SD 116 ± 35.2 105.0 ± 38.4 0.0643 
Triglycerides (mg/dL), mean ± SD 103.5± 53.3 117.6 ±58.4 0.11 
Creatinine (mg/dL), mean ± SD 0.9 ± 0.4 1.07 ± 0.6 0.06 
ALT (U/L), mean ± SD 16.6± 7.7 19.8 ±14.2 0.08 
AST (U/L), mean ± SD 18.3±6.2 22.4 ±12.2 0.0075 
Bilirubin (mg/dL), mean ± SD 0.8± 0.4 0.9 ±0.5 0.09 
Antiplatelet and/or anticoagulant drug use, n (%) 28 (35.4) 28 (35.4) 1 
Use of lipid-lowering drugs, n (%) 24 (30.4) 27 (34.2) 0.61 
* Blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic or taking antihypertensive medication. 
† Fasting plasma glucose ≥126 mg/dL and/or plasma glucose ≥200 mg/dL 2 hours after a 75-g oral glucose load or taking insulin or oral hypoglycemics. 
‡ Fasting plasma cholesterol ≥220 mg/dL or taking lipid-lowering drugs. 
 
Discussion 
G6PD deficiency is the most common enzyme 
deficiency in humans, with an estimated 400 million 
people affected worldwide.11 It has a high prevalence 
(5-30%) in the tropical and sub-tropical regions of the 
world, including Africa, Asia, the Middle East, the 
Mediterranean, and Papua New Guinea.22,23 In the 
U.S., Afro-American males are commonly affected, 
with a prevalence of 10%.23 The island of Sardinia is 
one of the areas with the highest prevalence, with 
rates of between 8 and 15%.12-18  
The geographic distribution of G6PD deficiency 
is highly correlated with the distribution of current or 
past malaria endemicity. This finding might be the 
result of a balanced polymorphism conferring 
resistance to infection with falciparum malaria.11 
Furthermore, recent research has found supportive 
evidence for protection against ischemic heart and 
cerebrovascular disease, RVO, NAION, and colorectal 
cancer in G6PD deficient individuals.14,16,19-21 Overall, 
these data seem to suggest that G6PD deficiency may 
have a protective effect against the development of 
various age-related diseases. 
The main risk factors for the development of 
late-stage AMD include ageing, genetics, ethnicity, 
and oxidative stress.3-9 Tobacco smoking is the main 
modifiable risk factor consistently identified in many 
studies;6,24 thus, stopping smoking is strongly 
recommended in patients at risk for AMD. A number 
of population-based and case-control studies have 
investigated the correlation between AMD, systemic 
hypertension, and other cardiovascular diseases.25-32 
These studies have reported conflicting results.  
Little is known about the role of G6PD deficiency 
in the pathogenesis of AMD. To the best of our 
knowledge, we are unaware of any previous 
investigation exploring a possible relationship 
between late-stage AMD and G6PD deficiency. In 
theory, a decrease in NADPH production might 
paradoxically result in protection against oxidative 
stress, as reported by a recent survey associating high 
G6PD activity and elevated NDAPH levels with 
endothelial and vascular dysfunction.33 In fact, 
G6PD-derived NADPH, a cofactor for NADPH 
oxidase, enhances superoxide anion generation, thus 
increasing oxidative stress.33 G6PD deficiency might 
also offer protection against choroidal 




microangiopathy because of the decreased cholesterol 
synthesis.15 
In our study, we found that late-stage AMD 
patients and cataract controls without AMD had 
similar values of G6PD prevalence (8.9% and 10.1%, 
respectively). Stepwise logistic regression analysis 
showed that G6PD deficiency has no significant 
protective effect against AMD, nor is a risk factor for 
this degenerative macular disorder. Even though 
there does not appear to be a substantial protective or 
enhancing effect of G6PD deficiency on the 
development of AMD, there is still the possibility of a 
less pronounced effect that is missed because of a type 
II error due to the relatively small sample size, largely 
dependent on the incidence of AMD. Indeed, if we, 
hypothetically, increased by 60 times the number of 
cases and controls (4,740 instead of 79) and 
maintained the same prevalence rates of G6PD 
deficiency as above, we would find a statistically 
significant protective effect of G6PD deficiency on 
late-stage AMD (OR = 0.86; 95% CI = 0.75-0.99; P = 
0.036). 
Our investigation also shows that late-stage 
AMD is significantly associated with higher values of 
diastolic blood pressure and LDL, even though, 
particularly for LDL, the OR is pretty small. Our 
results are consistent with former studies identifying 
systemic hypertension and serum cholesterol levels as 
risk factors for AMD,25,28,32,34-37 but conflicting with 
others.26,37,38 Lipid metabolism has long been 
hypothesized to be important in the pathogenesis of 
AMD.39 Indeed, lipid deposits in Bruch’s membrane 
represent at least 40% of the volume of drusen.40  
A correlation between systemic hypertension, 
cholesterol, and AMD would suggest the presence of 
shared risk factors for cardiovascular disease and 
AMD, and may support the hypothesis of a similar 
pathogenesis. However, in the present survey, AMD 
patients and control subjects without AMD had 
similar rates of cardio- and cerebro-vascular 
disorders, a result contrasting with the former 
hypothesis. 
In our study, we found that patients with AMD 
had a significantly lower WBC count; furthermore, 
AMD risk was significantly associated with lower 
values of WBC count. Previous epidemiological 
studies have shown conflicting results regarding the 
association between WBC count and AMD. Whereas 
multiple studies have reported correlations between 
higher WBC counts and an increased risk of 
AMD,36,41,42 other studies have failed to find such an 
association.43-45 This evidence is further complicated 
by our finding, showing an inverse correlation, i.e. 
that a higher WBC count is associated with a lower 
risk of AMD. Overall, these results suggest that the 
role of leukocyte count in AMD is far from clear. 
In our survey, patients with AMD had 
significantly lower values of AST, and AMD risk was 
significantly associated with lower AST values. We 
are unaware of any former study exploring a possible 
relationship between AMD and transaminases. The 
significance of our finding, implying that higher AST 
values may have a protective effect against AMD, 
remains obscure and needs further investigation. 
It is well known that smoking significantly 
increases the risk of AMD. Nevertheless, in our study, 
AMD patients and cataract controls without AMD 
had similar rates of smoking. This result does not 
come as a surprise, because smoking is a modifiable 
risk factor not only for AMD, but also for senile 
cataract.46-48 
In our investigation, the controls were selected 
among patients undergoing cataract surgery. We feel 
strongly that this strategy did not lead to a selection 
bias.49 Actually, the prevalence rate (10.1%) of G6PD 
deficiency in the control group was the same as in the 
male Sardinian population,13,17,18 a finding consistent 
with former large studies showing that G6PD 
deficient patients do not have a higher risk of 
developing cataract.17,50 
Our study has several important limitations, 
including its cross-sectional design and the relatively 
small sample size. Furthermore, it was restricted to a 
limited, genetically homogeneous group of patients 
(i.e. those of Sardinian descent). Therefore, our 
findings may not be applicable to AMD patients of 
non-Sardinian ancestry. Last, but not least, even 
though both wet and dry forms of AMD have 
common underlying pathological features and causes, 
we analyzed a small number of patients with 
geographic atrophy. 
In conclusion, our results suggest that G6PD 
deficiency has no protective effect against AMD, nor 
is a risk factor for this degenerative macular disorder. 
On the other hand, AMD was significantly associated 
with higher values of diastolic blood pressure and 
LDL and lower values of WBC count and AST. These 
findings need to be confirmed by larger scale studies, 
also involving patients of non-Sardinian ancestry. 
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